Prnewswire·2025-10-22 12:30Core Insights - Co-Diagnostics, Inc. is participating in the Global Health Exhibition 2025 in Riyadh, Saudi Arabia, showcasing its innovative molecular diagnostic technologies [1][3] - The company recently announced a Memorandum of Understanding (MOU) for a joint venture with a regional manufacturing and distribution company in Saudi Arabia, aimed at developing and commercializing its diagnostic products in the Middle East and North Africa [4][6] Company Participation - The executive leadership team, including CEO Dwight Egan and President Richard Abbott, will represent the company at the exhibition [2] - The exhibition is expected to attract over 160,000 healthcare professionals and numerous brands and investors from around the globe [3] Joint Venture Details - The anticipated joint venture will focus on the development, manufacture, and sale of Co-Diagnostics' intellectual property, including the Co-Dx PCR point-of-care platform [4] - The new platform and other infectious disease PCR products will be showcased at Booth H3.L17 during the exhibition [4][5] Company Overview - Co-Diagnostics, Inc. specializes in molecular diagnostics, developing technologies for detecting and analyzing nucleic acid molecules [6] - The company's proprietary technology is designed for specific tests related to its Co-Dx PCR platform, which is currently under regulatory review and not available for sale [5][6]